Med Sci (Paris)
Volume 37, Number 11, Novembre 2021
Nos jeunes pousses ont du talent !
Page(s) 1073 - 1076
Section Partenariat médecine/sciences - Écoles doctorales - Masters
Published online 01 December 2021
  1. Amirfakhryan H, Safari F. Outbreak of SARS-CoV2: pathogenesis of infection and cardiovascular involvement. Hellenic J Cardiol 2021; 62 : 13–23. [CrossRef] [PubMed] [Google Scholar]
  2. Bonny V, Maillard A, Mousseaux C, et al. Covid-19 : physiopathologie d’une maladie à plusieurs visages. Rev Med Interne 2020; 41 : 375–89. [CrossRef] [PubMed] [Google Scholar]
  3. D’Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of Covid-19 outbreak in Italy. Biosafety Health 2020; 2 : 57–9. [CrossRef] [Google Scholar]
  4. Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep Med 2020; 1 : 100059. [CrossRef] [PubMed] [Google Scholar]
  5. Chen S, Einspanier R, Schoen J. Transepithelial electrical resistance (TEER): a functional parameter to monitor the quality of oviduct epithelial cells cultured on filter supports. Histochem Cell Biol 2015 ; 144 : 509–515. [CrossRef] [PubMed] [Google Scholar]
  6. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9 : eaal3653. [CrossRef] [PubMed] [Google Scholar]
  7. Pizzorno A, Terrier O, Nicolas de Lamballerie C, et al. Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Front Immunol 2019 ; 10 : 60. [CrossRef] [PubMed] [Google Scholar]
  8. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19. Interim WHO solidarity trial results. N Engl J Med 2021; 384 : 497–511. [CrossRef] [PubMed] [Google Scholar]
  9. Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMed 2021; 65 : 103255. [CrossRef] [Google Scholar]
  10. University of Aarhus. The impact of camostat mesilate on Covid-19 infection: an investigator-initiated randomized, placebo-controlled, phase IIa trial., 2021. [Google Scholar]
  11. Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for Covid-19. Viruses 2021; 13 : 628. [CrossRef] [PubMed] [Google Scholar]
  12. Falcone M, Tiseo G, Valoriani B, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe Covid-19 and role of variants of concern. Infect Dis Ther 2021; Aug 25, pp. 1–10, doi: 10.1007/s40121-021-00525-4. [Google Scholar]
  13. Meo SA, Bukhari IA, Akram J, et al. Covid-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 2021; 25 : 1663–9. [Google Scholar]
  14. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396 : 1979–93. [Google Scholar]
  15. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397 : 881–91. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.